Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…